NxStage Medical (NASDAQ:NXTM) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday.
According to Zacks, “NxStage Medical, Inc. is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. “
Several other equities research analysts have also recently weighed in on NXTM. Canaccord Genuity reiterated a “hold” rating and set a $30.00 price objective on shares of NxStage Medical in a research report on Tuesday, October 17th. Northland Securities reiterated a “hold” rating and set a $30.00 price objective on shares of NxStage Medical in a research report on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating and nine have assigned a hold rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $30.25.
In other news, SVP Winifred L. Swan sold 3,500 shares of the stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $25.73, for a total transaction of $90,055.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last quarter, insiders have sold 10,500 shares of company stock valued at $275,030. 4.70% of the stock is currently owned by corporate insiders.
Large investors have recently bought and sold shares of the business. Prudential Financial Inc. bought a new position in shares of NxStage Medical in the third quarter valued at $202,000. Amalgamated Bank lifted its stake in shares of NxStage Medical by 7.1% in the second quarter. Amalgamated Bank now owns 8,357 shares of the medical device company’s stock valued at $210,000 after buying an additional 553 shares in the last quarter. Athos Capital Ltd bought a new position in shares of NxStage Medical in the third quarter valued at $557,000. Suntrust Banks Inc. lifted its stake in shares of NxStage Medical by 2.3% in the second quarter. Suntrust Banks Inc. now owns 9,480 shares of the medical device company’s stock valued at $237,000 after buying an additional 209 shares in the last quarter. Finally, BNP Paribas Arbitrage SA lifted its stake in shares of NxStage Medical by 217.0% in the second quarter. BNP Paribas Arbitrage SA now owns 9,676 shares of the medical device company’s stock valued at $243,000 after buying an additional 6,624 shares in the last quarter. Institutional investors and hedge funds own 85.35% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece was reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/03/nxstage-medical-nxtm-stock-rating-upgraded-by-zacks-investment-research.html.
NxStage Medical Company Profile
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.